Effect of tumor-infiltrating lymphocytes depending on the presence of postmastectomy radiotherapy on the prognosis in pT1-2N1M0 breast cancer

Background Currently, it remains unclear regarding the association between tumor-infiltrating lymphocytes (TILs) and the efficacy of postoperative radiotherapy in primary tumors. Here we attempted to investigate the effect of TILs depending on the presence of postmastectomy radiotherapy (PMRT) on the prognosis in pT1-2N1M0 breast cancer. Methods The clinical data of pT1-2N1M0 breast cancer patients undergoing mastectomy and axillary lymph node dissection were retrospectively analyzed. The effect of TILs on the prognosis was assessed based on the infiltration degree (low: TILs ≤10%, high: TILs >10%), and then the prognosis of patients with low and high infiltration of TILs was analyzed based on presence or absence of PMRT. Results Totally 213 patients were eligible for the study, including 162 cases of low infiltration and 51 of high infiltration. High-infiltration patients tended to be ER/PR-negative, HER2-positive, and have high histological grade. The infiltration in triple-negative and HER2-positive subtypes was higher compared with Luminal A subtype. Regarding local-regional recurrence-free survival, recurrence-free survival, and overall survival (OS) rates, the differences were all inapparent whether in high- and low-infiltration patients or in high-infiltration patients with/without PMRT. Compared with those without PMRT, low-infiltration patients with PMRT showed a significantly increased OS rate (92.8% vs. 80.0%, p=0.023). Multivariate analysis further confirmed PMRT as an independent predicator of OS in low-infiltration patients (HR: 0.228, 95%CI: 0.081-0.644, p=0.005). Conclusion High infiltration of TILs in pT1-2N1M0 breast cancer may be associated with clinicopathological factors. Low-infiltration patients, but not high-infiltration patients, may derive survival benefits from PMRT.

[1]  P. Bendahl,et al.  Low levels of WRAP53 predict decreased efficacy of radiotherapy and are prognostic for local recurrence and death from breast cancer: a long-term follow-up of the SweBCG91RT randomized trial. , 2023, Molecular Oncology.

[2]  Biaoru Li.  Why do tumor-infiltrating lymphocytes have variable efficacy in the treatment of solid tumors? , 2022, Frontiers in Immunology.

[3]  M. Rinaldo,et al.  Identification of Immune Cell Components in Breast Tissues by a Multiparametric Flow Cytometry Approach , 2022, Cancers.

[4]  J. Overgaard,et al.  Tumor-infiltrating lymphocytes predict improved overall survival after post-mastectomy radiotherapy: a study of the randomized DBCG82bc cohort , 2021, Acta oncologica.

[5]  S. Luoh,et al.  Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer , 2021, Cancer and Metastasis Reviews.

[6]  D. Danforth,et al.  The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer. , 2020, Clinical breast cancer.

[7]  Zemin Zhang,et al.  The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications , 2020, Cellular & Molecular Immunology.

[8]  A. Russo,et al.  Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? , 2018, Cellular immunology.

[9]  M. Fernö,et al.  Response to Radiotherapy After Breast-Conserving Surgery in Different Breast Cancer Subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Ralph R. Weichselbaum,et al.  Radiotherapy and immunotherapy: a beneficial liaison? , 2017, Nature Reviews Clinical Oncology.

[11]  Joe Y. Chang,et al.  Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? , 2016, Nature Reviews Clinical Oncology.

[12]  C. Drake,et al.  Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. , 2015, The Lancet. Oncology.

[13]  Carsten Denkert,et al.  Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. , 2015, JAMA oncology.

[14]  Carsten Denkert,et al.  Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Molin Wang,et al.  Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S Michiels,et al.  Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Carsten Denkert,et al.  Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial , 2013, PloS one.

[19]  Stefan Michiels,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Demaria,et al.  Radiation therapy to convert the tumor into an in situ vaccine. , 2012, International journal of radiation oncology, biology, physics.

[21]  H. Mouridsen,et al.  [Danish Breast Cancer Cooperative Group]. , 2012, Ugeskrift for laeger.

[22]  R. Fietkau,et al.  Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation - implications for cancer therapies. , 2012, Current medicinal chemistry.

[23]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[24]  R. Weichselbaum,et al.  The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. , 2011, Cancer research.

[25]  J. Adolfsson,et al.  Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data , 2011, The Lancet.

[26]  L. Zitvogel,et al.  Chemotherapy and radiotherapy: cryptic anticancer vaccines. , 2010, Seminars in immunology.

[27]  Torgny Stigbrand,et al.  Radiation-induced cell death mechanisms , 2010, Tumor Biology.

[28]  S. Demaria,et al.  Up-regulation of the Pro-inflammatory Chemokine CXCL16 is a Common Response of Tumor Cells to Ionizing Radiation , 2010, Radiation research.

[29]  F. B. Sørensen,et al.  Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Gerber,et al.  Radiation-Induced IFN-γ Production within the Tumor Microenvironment Influences Antitumor Immunity1 , 2008, The Journal of Immunology.

[31]  I. Lax,et al.  Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma , 2006, Acta oncologica.

[32]  W. Symmans,et al.  Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  Antonin Bukovsky,et al.  Multifaceted Regulation of Cell Cycle Progression by Estrogen: Regulation of Cdk Inhibitors and Cdc25A Independent of Cyclin D1-Cdk4 Function , 2001, Molecular and Cellular Biology.

[34]  Mike Clarke,et al.  EFFECTS OF RADIOTHERAPY AND SURGERY IN EARLY BREAST-CANCER - AN OVERVIEW OF THE RANDOMIZED TRIALS , 1995 .

[35]  Anthony Howell,et al.  Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. , 1995, The New England journal of medicine.

[36]  S. Rosenberg,et al.  Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[37]  M. Lederman.  Immunotherapy in treatment of breast cancer. , 1974, Proceedings of the Royal Society of Medicine.

[38]  M. Fernö,et al.  Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes: A Long-Term Follow-Up of the SweBCG91RT Randomized Trial. , 2019, Journal of Clinical Oncology.

[39]  Amy M. Sitapati,et al.  NCCN Guidelines Insights: Breast Cancer, Version 1.2017. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[40]  D. Roy,et al.  Estrogen-induced reactive oxygen species-mediated signalings contribute to breast cancer. , 2011, Biochimica et biophysica acta.

[41]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.